11 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 18 Phase 3, 2 Phase 2.
By phase and status
Follow R-Pharm: new trials by email
Trials (filtered) newest first · largest first
All 18 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
RPH-104 - Familial Mediterranean Fever, FMF | Phase 3 | Not yet recruiting | 18 | 2026-12-01 | 2026-10-19 |
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
RPH-051, Docetaxel, Perjeta® - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Active not recruiting | 246 | 2024-08-09 | 2026-07-14 |
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
RPH-002, Erbitux®, Cisplatin - Head and Neck Squamous Cell Carcinoma | Phase 3 | Completed | 161 | 2024-08-08 | 2026-07-14 |
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
RPH-075, Keytruda® - Skin Melanoma | Phase 3 | Completed | 266 | 2023-09-27 | 2026-07-15 |
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL - Lung Diseases, Interstitial | Phase 2 / Phase 3 | Recruiting | 138 | 2023-08-23 | 2024-11-19 |
Study of Efficacy of Different Treatment Regimens of Olokizumab
Olokizumab, Standard therapy - COVID-19 | Phase 3 | Unknown | 198 | 2021-07-08 | 2023-02-13 |
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
RPH-104 - Idiopathic Recurrent Pericarditis | Phase 3 | Active not recruiting | 17 | 2020-12-11 | 2024-11-15 |
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
Olokizumab 64 mg, Placebo - COVID-19 | Phase 2 / Phase 3 | Withdrawn | | 2020-06-30 | 2021-11-08 |
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Favipiravir, Standard of care (SOC), standard concomitant therapy - COVID-19 | Phase 3 | Completed | 168 | 2020-05-20 | 2023-01-20 |
Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia
Remimazolam, Propofol, Fentanyl - General Anaesthesia | Phase 3 | Completed | 150 | 2017-08-22 | 2018-09-13 |
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | 300 | 2016-07-18 | 2019-05-21 |
Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
Nemonoxacin, Tavanic, Placebo (250 ml) - Pneumonia, Bacterial | Phase 3 | Completed | 342 | 2016-05-04 | 2023-02-16 |
Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence
Odelepan, Placebo - Alcohol Dependence | Phase 3 | Completed | 644 | 2014-11-18 | 2019-05-22 |
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)
Narlaprevir, Ritonavir, Placebo Narlaprevir - Hepatitis C | Phase 3 | Completed | 420 | 2014-05-07 | 2019-02-07 |
Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
Fimasartan, Losartan - Arterial Hypertension | Phase 3 | Completed | 179 | 2014-05-01 | 2019-05-06 |
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
Ixabepilone, Doxorubicin, Paclitaxel - Endometrial Cancer | Phase 3 | Terminated | 551 | 2009-08-01 | 2017-03-09 |
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Ixabepilone + Capecitabine, Capecitabine - Cancer, Breast Cancer | Phase 3 | Completed | 1221 | 2003-11-01 | 2020-11-02 |
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | 752 | 2003-09-01 | 2020-11-02 |
Conditions studied
Breast Neoplasms (3) · COVID-19 (3) · Lung Diseases (2) · Neoplasms (2) · Respiration Disorders (2) · Alcoholism (1) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Endometrial Neoplasms (1) · Familial Mediterranean Fever (1) · Hepatitis C (1) · Hypertension (1) · Lung Diseases, Interstitial (1) · Melanoma (1) · Neoplasm Metastasis (1)
Interventions
ixabepilone (3) · Capecitabine (2) · Docetaxel (2) · Epothilones (2) · Standard of Care (2) · olokizumab (2) · Cetuximab (1) · Cisplatin (1) · Doxorubicin (1) · Fentanyl (1) · Injections, Subcutaneous (1) · LY2196044 (1) · Levofloxacin (1) · Losartan (1) · Ofloxacin (1)
Countries
Russia (16) · Argentina (3) · Belgium (3) · Brazil (3) · Canada (3) · France (3) · Greece (3) · Italy (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · China (2) · Czechia (2) · Denmark (2)
Top investigators
Mikhail Samsonov (13)
Results publications
PMID 21128114, PMID 21937232, PMID 24472478, PMID 17968020, PMID 25925990, PMID 29522361
NIH funding
2008 (1)